Dr. Chen Jing, PhD graduate from the University of Hong Kong, has over a decade of experience in health service research and clinical studies. Before joining the Chinese University of Hong Kong (CUHK), she made impactful contributions across diverse healthcare sectors, including academic institutions, the Food and Health Bureau of the Hong Kong Special Administrative Region (HKSAR), and the healthcare industry.

 

Her research has intricately focused on evaluations of interventions in chronic diseases and the implementation of public health policies. Her economic evaluations, spanning community-based smoking cessation interventions for Chronic Obstructive Pulmonary Disease (COPD) patients, diabetic eye disease screening for those with diabetes, abdominal aortic aneurysm (AAA) screening for heart disease patients, and tobacco control policies in the general population, have yielded pivotal evidence. This evidence has supported the establishment of AAA screening in public hospitals, the broader implementation of tobacco control policies, and enhancements to community-based smoking cessation services.

 

Dr. Chen's research passion extends from health service research to clinical studies, where she collaborates with globally renowned clinicians. Leading multiple clinical studies on HBV, HCV, and liver cancer, she partnered with specialists in Hong Kong and mainland China. Their investigator-initiated trials on DAAs for personalized HCV treatment and HBV/HCV co-infections have affirmed efficacy and safety of DAAs in real-world settings. This groundbreaking work has influenced treatment guidelines globally, with DAAs personalized treatments for HCV now integrated into Asian guidelines (APASL) and DAAs treatment for HBV-HCV co-infections included in guidelines across the United States (AASLD), Europe (EASL), and Asia (APASL).

 

Simultaneously, she led a series of economic evaluations on the cost-effectiveness and affordability of DAAs. Collaborating with international and local liver disease experts, these evaluations played a pivotal role in securing DAA approval in China. Spanning all provinces, they facilitated the integration of DAAs into Chinese Health Insurance, benefiting tens of thousands of HCV patients. The outcomes of these studies have been featured in esteemed international journals such as Hepatology, Lancet Gastroenterol Hepatol, and Clinical Gastroenterology and Hepatology.

 

As a trained public health researcher, Dr. Chen, in her Researcher role at FHB in HKSAR, focused on policy research on overseas health systems and best practices, providing evidence for decision-makers on topics including cancer services, primary care, and tobacco control policies. Amid the onset of Covid-19 in late 2019, she immersed herself in commissioned research, involving the creation of dynamic dashboards for local situations, literature reviews on clinical perspectives of Covid-19, and policy reviews for Covid-19 control worldwide. Though intense, this aligns with her professional training and passion.

 

In her current academic position at CUHK, Dr. Chen actively engages in research centered on developing and evaluating diverse healthcare service models in Hong Kong and China mainland. Her dedication extends to screening and self-sampling initiatives, facilitating early detection and treatment for diseases such as HBV and HPV. Dr. Chen's multifaceted contributions underscore her unwavering commitment to advancing healthcare research and improving public health outcomes.